Tulsi (Holy Basil) for Type 2 Diabetes

Verdict: Weak, unproven signal — not a treatment

A few small, mostly dated trials suggest tulsi (holy basil) might modestly lower fasting blood glucose, but the evidence is too thin and inconsistent to recommend it for type 2 diabetes. It should never replace proven diet, exercise, or medication.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The positive signal rests on a single classic trial and one pooled analysis. A 1996 single-blind crossover RCT in 40 people with type 2 diabetes (PMID 8880292) found fasting glucose dropped about 21 mg/dl (roughly 18%) on holy basil leaves versus placebo. A 2018 meta-analysis (Jamshidi, Journal of Functional Foods; not PubMed-indexed) pooled trials to a fasting-glucose reduction of about 16 mg/dl, but with extreme heterogeneity (I-squared 91%), meaning the trials disagreed sharply.

The grade stays low because the underlying studies are small, mostly Indian, methodologically dated, and prone to publication bias — and critically, none used HbA1c, the standard long-term glucose marker, as a primary endpoint. A separate 2017 trial (PMID 28811698) improved insulin resistance but enrolled young, non-diabetic overweight adults and never measured glucose. A large 2023 network meta-analysis of antidiabetic herbs (PMID 37451111) did not even include tulsi, underscoring how much thinner its evidence is than fenugreek, cinnamon, or apple cider vinegar.

Authorities do not endorse it. The American Diabetes Association states there is insufficient evidence to support routinely using herbal supplements to improve glycemia; the WHO monograph notes traditional use for diabetes but calls the clinical data inadequate; and the FDA merely lists the plant without any health endorsement. Anyone taking glucose-lowering medication should be cautious and consult a clinician, given the theoretical added risk of low blood sugar.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.55
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.42
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.547
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus
PMID: 8880292 1996 RCT (open-label) n = 40
Finding: Classic crossover RCT in NIDDM: fasting blood glucose fell 21.0 mg/dl (17.6% reduction, p<0.001) and postprandial glucose fell 15.8 mg/dl (7.3% reduction, p<0.02) during holy basil treatment vs placebo; mild reduction in total cholesterol. Authors suggest basil leaves as adjunct to diet and drug therapy in mild-to-moderate NIDDM.
🟠 Limited quality Effect size: Fasting glucose MD -21.0 mg/dl; postprandial glucose MD -15.8 mg/dl
View on PubMed
Holybasil (tulsi) lowers fasting glucose and improves lipid profile in adults with metabolic disease: A meta-analysis of randomized clinical trials
PMID: 2018 統合分析
— See PubMed for details
View on PubMed
Effect of Tulsi (Ocimum sanctum Linn.) Supplementation on Metabolic Parameters and Liver Enzymes in Young Overweight and Obese Subjects
PMID: 28811698 2017 RCT (open-label) n = 30
Finding: Parallel open-label pilot RCT in young overweight/obese (non-diabetic) subjects: significant improvement in triglycerides (p=0.019), LDL (p=0.001), HDL (p=0.001), VLDL (p=0.019), BMI (p=0.005), plasma insulin (p=0.021) and insulin resistance/HOMA-IR (p=0.049); no adverse liver enzyme changes. Postprandial glucose and HbA1c not assayed.
🟠 Limited quality Effect size: HOMA-IR significantly reduced (p=0.049); plasma insulin reduced (p=0.021); glucose endpoints not reported
View on PubMed
Comparative effectiveness of six herbs in the management of glycemic status of type 2 diabetes mellitus patients: A systematic review and network meta-analysis of randomized controlled trials
PMID: 37451111 2023 統合分析 n = 3,130
Finding: Network meta-analysis of 44 RCTs (3130 participants): apple cider vinegar, fenugreek, curcumin and cinnamon significantly reduced fasting glucose; only ACV and fenugreek reduced HbA1c. Ocimum sanctum / tulsi was NOT among the six herbs evaluated, so this MA provides no direct tulsi estimate but contextualises tulsi's evidence base as thinner than other antidiabetic herbs.
Effect size: Not applicable to tulsi (tulsi not included as a comparator herb)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
OCIMUM TENUIFLORUM TOP source↗
L4e WHO
Neutral
Folium Ocimi Sancti source↗
L5e Specialty Society (condition-mapped)
Against
There is insufficient evidence to support the routine use of herbal supplements and micronutrients, such as cinnamon, curcumin (e.g., turmeric), aloe vera, or chromium, to improve glycemia in people with type 1 or type 2 diabetes. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-type2-diabetes-INT-tulsi-001 繁體中文版 →